Lung cancer trials in China

In China 1144 Also abroad 2746

1,144 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Where
Beijing
Age
18 years and over
People
144
Run by
Peking Union Medical College Hospital
See details and how to joinNCT06674343
Phase 2Taking people
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Where
Changsha
Age
18 years and over
People
6,000
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT04322890
No phaseNot yet taking people in China
A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer
Where
Shenzhen
Age
18 years to 70 years
People
12
Run by
BioSyngen Pte Ltd
See details and how to joinNCT06643910
Phase 3Taking people
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Where
Shanghai
Age
18 years and over
People
632
Run by
Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT05487391
No phaseEnrolling by invitation
Comparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study
Where
Xi'an
Age
18 years to 75 years
People
660
Run by
Xiaolong Yan, Dr.
See details and how to joinNCT06028412
Phase 1/2Taking people
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Where
Beijing
Age
16 years to 90 years
People
85
Run by
Essen Biotech
See details and how to joinNCT06538012
Phase 1/2Taking people
Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers
Where
Guangzhou
Age
18 years to 75 years
People
20
Run by
Zhou Chengzhi
See details and how to joinNCT06607770
Phase 2Not yet taking people in China
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
Where
Changsha
Age
18 years and over
People
30
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT06634667
Phase 3Taking people
Segmentectomy for Solid-dominant Lung Cancer
Where
Shanghai
Age
18 years to 80 years
People
277
Run by
Fudan University
See details and how to joinNCT06634966
No phaseTaking people
AI-Assisted Non-Contrast CT for Multi-Cancer Screening
Where
Shanghai
Age
18 years and over
People
1,000,000
Run by
Guo ShiWei
See details and how to joinNCT06632886
No phaseTaking people
The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
Where
Shanghai
Age
18 years to 75 years
People
30
Run by
Ruijin Hospital
See details and how to joinNCT06623487
Early phase 1Not yet taking people in China
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
Where
Shanghai
Age
18 years to 75 years
People
9
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT06619886
Phase 2Not yet taking people in China
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
Where
Shanghai
Age
18 years and over
People
296
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT06620822
Phase 3Taking people
Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
Where
Guangzhou
Age
18 years to 75 years
People
180
Run by
Zhou Chengzhi
See details and how to joinNCT06607796
Phase 2Taking people
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Where
Changsha
Age
18 years and over
People
90
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT05014464
Phase 2Taking people
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Where
Changsha
Age
18 years and over
People
100
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT06355609
Phase 2Taking people
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
Where
Shanghai
Age
18 years and over
People
100
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT05766800
No phaseTaking people
Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma
Where
Wuhan
Age
20 years to 80 years
People
3,000
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT05830812
Phase 2Taking people
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
Where
Huizhou, Lianyungang, Nanyang, Tianjin, Weihai
Age
18 years to 75 years
People
148
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06141226
Phase 2Taking people
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
Where
Changsha
Age
18 years and over
People
52
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT06348927
Phase 1/2Taking people
Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer
Where
Hefei
Age
18 years to 70 years
People
45
Run by
Anhui Provincial Hospital
See details and how to joinNCT06527898
Phase 1Not yet taking people in China
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
Where
Wuhan
Age
18 years and over
People
350
Run by
Jiangsu Hansoh Pharmaceutical Co., Ltd.
See details and how to joinNCT06594874
Phase 2Not yet taking people in China
Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction
Where
Changsha
Age
18 years to 80 years
People
39
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT06604351
Phase 1Not yet taking people in China
Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
Where
Guangzhou
Age
18 years to 75 years
People
20
Run by
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT06585059
Phase 2Not yet taking people in China
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
Where
Shanghai
Age
18 years and over
People
44
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT06585644